Jazz Pharmaceuticals, Inc.
Please visit us at the Jazz Pharmaceuticals Booth #419.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.
Jazz Pharmaceuticals markets DEFITELIO® (defibrotide sodium), RYLAZE® (asparaginase erwinia chrysanthemi (recombinant)-rywn), VYXEOS® (daunorubicin and cytarabine) liposome for injection, ZEPZELCA™ (lurbinectedin), EPIDIOLEX® (cannabidiol), SUNOSI® (solriamfetol), and XYWAV® (calcium, magnesium, potassium, and sodium oxybates) in the U.S.
Brands: DEFITELIO, RYLAZE, VYXEOS, ZEPZELCA, EPIDIOLEX, SUNOSI AND XYWAV